U.S. markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.09 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.88 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9842
    +0.0022 (+0.23%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1120
    -0.0003 (-0.03%)
     
  • USD/JPY

    144.4950
    +0.0520 (+0.04%)
     
  • BTC-USD

    19,219.08
    -84.33 (-0.44%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.89 (-1.84%)
     

Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger

·1 min read
  • HC Wainwright assumes coverage on Immunic Inc (NASDAQ: IMUX), a late-stage clinical biotech company developing oral small molecule inhibitors for multiple sclerosis (MS) and psoriasis.

  • The analyst issued a Buy call on the stocks with a price target of $26.

  • Lead drug vidofludimus calcium (IMU-838) is a novel oral DHODH inhibitor and Farnesoid X receptor (FXR) ligand currently in Phase 3 trials for relapsing MS (RMS) and Phase 2 trials for progressive MS (PMS).

  • HC Wainwright notes FDA-approved Sanofi SA (NASDAQ: SNY) Aubagio is a DHODHi, but without a clean safety profile, it still generated over $2 billion in sales in 2020.

  • IMU-838 has already succeeded in a Phase 2 trial for MS with a clean safety profile.

  • IMU-838 showed significant protection against serum neurofilament level (sNfL) increases, a neuronal damage marker, similar to reductions seen with Roche Holding AG's (OTC: RHHBY) successful Ocrevus, relatively recent (2017) launch in the "crowded" Multiple Sclerosis space.

  • The analyst notes that IMU-838 could be the first oral to offer neuroprotection to Multiple Sclerosis patients and will gain market share in progressive MS, making its launch distinct from other oral MS drugs.

  • Price Action: IMUX shares are trading at $3.91 on the last check Monday.

Latest Ratings for IMUX

Date

Firm

Action

From

To

Sep 2021

HC Wainwright & Co.

Maintains

Buy

Apr 2021

Aegis Capital

Initiates Coverage On

Buy

Mar 2021

JMP Securities

Initiates Coverage On

Market Outperform

View More Analyst Ratings for IMUX

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.